The clinical candidate MDM2 antagonist Idasanutlin is currently in a phase I trial in patients with PV or ET, with a provision for adding pegylated IFN in subjects without or with partial remission after three cycles of therapy. This evidence concerns the gene IFNA1 and acquired polycythemia vera.